Kyowa Kirin

Kyowa Kirin Co., Ltd. (協和キリン株式会社, Kyōwa Kirin Kabushiki Kaisha) is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and is among the 40 largest in the world by revenue. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index.^[4][5]

Kyowa Kirin Co., Ltd.

Headquarters in Otemachi, Chiyoda, Tokyo
Formerly	Kyowa Hakko Kogyo Co., Ltd. (1949–2008)
Company type	Public
Traded as	TYO: 4151 Nikkei 225 Component
Industry	Pharmaceuticals Biotechnology
Predecessor	Kirin Pharma
Founded	July 1, 1949; 76 years ago (1949-07-01)
Headquarters	Ohtemachi Building, 1-6-1, Ōtemachi, Chiyoda-ku, Tokyo 100–8185, Japan
Key people	Nobuo Hanai, (CEO and president)
Products	Biochemicals Biosimilars Diagnostics Pharmaceuticals
Revenue	$ 2.99 billion USD (FY 2022) (¥ 398.4 billion JPY) (FY 2022)
Net income	$ 375 million USD (FY 2022) (¥ 53.6 billion JPY) (FY 2022)
Number of employees	7,532 (consolidated) (as of December 31, 2017)
Parent	Kirin Holdings Company, Limited
Subsidiaries	47 (33 in Japan and 14 overseas countries)
Website	Official website
Footnotes / references [1][2][3]

History

On July 1, 1949 the forerunner of the present company, Kyowa Hakko Kogyo Co., Ltd. is established. The company merged with Kirin Pharma Co., Ltd., on October 1, 2008 to form Kyowa Hakko Kirin with plans to spin off the bio-chemical business into Kyowa Hakko Bio.^[6]

On July 11, 2014, the KHK subsidiary, ProStrakan Group (based in Scotland), acquired Archimedes Pharma from the Novo Nordisk Foundation for $394 million ^[7]

In 2019, Kirin Holdings acquired 95% stake in Kyowa Hakko Bio which is Kyowa Kirin's subsidiary corporation.^[8] The entity was renamed "Kyowa Kirin Co., Ltd.", replacing its prior name of Kyowa Hakko Kirin Co., Ltd.

In November 2022, Kyowa Kirin announced plans to spin its international established medicines portfolio into a new joint venture with German company Grünenthal.^[9]

In October 2023, Kyowa Kirin acquired a Britain-based biopharmaceutical company, Orchard Therapeutics, for $478 million.^[10]

Business segments and products

• Pharmaceuticals business

The company developed a method to make afucosylated monoclonal antibodies using a CHO cell line in which FUT8 has been knocked out; the company calls this its "Potelligent" platform. The company gained marketing approval in Japan in April 2012 for a monoclonal antibody drug called mogamulizumab which was developed using the platform.^[11]

• • Central nervous system medicines
  • Immunology/Allergy medicines
  • Nephrology medicines
    • ESPO / NESP / Aranesp
    • REGPARA
  • Oncology medicines
    • ABSTRAL
    • GRAN / Peglasta / Neulasta
    • LEUNASE
    • Mitomycin-C
    • SANCUSO
  • Diagnostics
    • In vitro diagnostic reagents, analyzers and companion diagnostics
• Bio-Chemicals business
  • Biosimilars
  • Monoclonal Antibodies
  • Amino acids, nucleic acids and related compounds, health care products and other active pharmaceutical ingredients
  • Vitamins, minerals, peptides and plant growth regulators^[12]